{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36.4"}]}],"title":"ACR 20%"},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.2"}]}],"title":"ACR 50%"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.5"}]}],"title":"ACR 70%"}],"denoms":[{"counts":[{"groupId":"OG000","value":"66"}],"units":"Participants"}],"description":"Improvement must be seen in tender and swollen joint counts (28 assessed joints) and in at least 3 of the following 5 parameters: Separate patient and physician assessments of patient disease activity in the previous 24 hours on a visual analog scale (VAS, the extreme left end of the line \"no disease activity\" \\[symptom-free and no arthritis symptoms\\] and the extreme right end \"maximum disease activity\"; patient assessment of pain in previous the 24 hours on a VAS (extreme left end of the line \"no pain\" and the extreme right end \"unbearable pain\"); Health Assessment Questionnaire-Disability Index (20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, 0=without difficulty to 3=unable to do); and C reactive protein or, if missing, erythrocyte sedimentation rate.","groups":[{"description":"Patients received 2 intravenous infusions of rituximab 1000 mg, 14 days apart + methotrexate 10-25 mg/wk orally or subcutaneously during the Treatment Period.","id":"OG000","title":"Rituximab + Methotrexate (Group A)"}],"paramType":"NUMBER","populationDescription":"Safety population: All patients who received any amount of rituximab or any vaccine. Since only limited efficacy data were collected in this study, the parameters necessary to calculate the ACR20/50/70 responses were only available for patients in Group A.","reportingStatus":"POSTED","timeFrame":"Week 24","title":"Percentage of Patients in Group A With an Improvement of at Least 20%, 50%, or 70% in American College of Rheumatology (ACR) Score (ACR20/50/70) From Baseline at Week 24","type":"SECONDARY","unitOfMeasure":"Percentage of patients"}